Muscle Protein Breakdown

Muscle protein breakdown (MPB), also called muscle proteolysis, is the catabolic counterpart of muscle protein synthesis. Together, MPS and MPB constitute the continuous turnover of skeletal muscle protein; their net balance determines whether muscle mass is maintained, accreted, or lost. Approximately 1-2% of total muscle protein is degraded and resynthesized per day in healthy adults.

Proteolytic systems

Three principal proteolytic systems operate in skeletal muscle. The ubiquitin-proteasome system (UPS) tags damaged, misfolded, or regulatory proteins with polyubiquitin chains for recognition and degradation by the 26S proteasome — this pathway handles the majority of myofibrillar protein turnover. Key muscle-specific E3 ubiquitin ligases include MuRF1 (TRIM63) and MAFbx/Atrogin-1 (FBXO32). The autophagy-lysosomal system engulfs organelles, protein aggregates, and cytoplasmic components in double-membrane autophagosomes that fuse with lysosomes. The calpain system of calcium-dependent proteases cleaves sarcomeric proteins, often preparing substrates for subsequent UPS degradation.

Hormonal and nutritional regulation

Insulin is the dominant physiological inhibitor of MPB. Rennie, Wilkes, and colleagues demonstrated that postprandial insulin elevation suppresses whole-body and muscle proteolysis by 30-50% from fasted rates, independent of amino acid concentration. This explains why hyperinsulinemic-euglycemic clamp conditions alone — without amino acid provision — shift net muscle protein balance into positive territory through MPB suppression rather than MPS stimulation. Leucine has a modest, secondary inhibitory effect on MPB in addition to its dominant stimulatory effect on MPS.

Catabolic conditions

Pathological MPB elevation occurs in disuse (bed rest, limb immobilization, spinal cord injury), systemic inflammation (sepsis, trauma, burn injury), cancer cachexia (driven by TNF-alpha, IL-6, myostatin, and tumor-derived factors), chronic kidney disease, glucocorticoid excess (Cushing syndrome, chronic corticosteroid therapy), and type 1 diabetes (insulin deficiency). In these states, MPB increases disproportionately to any MPS change, producing net loss of lean mass.

Aging and MPB

Unlike MPS, basal MPB is not consistently elevated in healthy older adults; sarcopenia is driven primarily by MPS insufficiency (anabolic resistance) rather than MPB excess. However, acute catabolic insults (hospitalization, infection, injury) in older adults produce larger MPB excursions from baseline than in younger adults, contributing to the "catabolic crisis" phenomenon of accelerated muscle loss during acute illness.

Measurement methodology

MPB is more challenging to measure than MPS. Arteriovenous balance techniques across a limb, combined with tracer dilution (L-[ring-2H5]-phenylalanine), yield net protein balance and can disaggregate MPS and MPB estimates. Urinary 3-methylhistidine excretion — a modified amino acid released only from myofibrillar protein degradation — provides a non-invasive measure of myofibrillar breakdown, though dietary meat intake confounds and must be controlled.

Clinical intervention targets

Therapeutic MPB suppression is a longstanding pharmaceutical target, particularly for cachexia and sarcopenia. Myostatin inhibitors, anti-IL-6 agents (tocilizumab), and selective androgen receptor modulators have shown promise in specific conditions. Nutritional approaches to MPB — ensuring adequate protein, calorie, and particularly leucine intake; limiting prolonged fasting; resistance training — remain the first-line strategies.